Chemokine receptors and chemokines in HIV infection

Journal of Clinical Immunology

Volumn 18, Issue 4, 1998, Pages 243-255

  Garzino Demo, Alfredo ^a   Devico, Anthony L ^a   Gallo, Robert C ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Chemokine receptors; Chemokines; HIV

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR;

ARTICLE; CYTOTOXIC T LYMPHOCYTE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS PATHOGENESIS;

CHEMOKINES; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CHEMOKINE;

EID: 0031857365     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1027329721892     Document Type: Article

References (159)

1. + T cells. Science 270:1811-1815, 1995
2. Cohen OJ, Kinter A, Fauci AS: Host factors in the pathogenesis of HIV disease. Immunol Rev 159:31-48, 1998
3. Dalgleish AG, Beverley PCL, Clapham PR, Crawford DH, Greaves MF, Weiss RA: The CD4 antigen is an essential component of the receptor for the AIDS virus. Nature 312:763-766, 1984
4. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman JC, Montagnier L: T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312:767-768, 1984
5. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47:333-348, 1986
6. Ashorn PA, Berger EA, Moss B: Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells. J Virol 64:2149-2156, 1990
7. Chesebro B, Buller R, Portis J, Wehrly K: Failure of human immunodeficiency virus entry and infection in CD4-positive human brain and skin cells. J Virol 64:215-221, 1990
8. Clapham PR, Blanc D, Weiss RA: Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus. Virology 181:703-715, 1991
9. Weiner DB, Huebner K, Williams WV, Greene MI: Human genes other than CD4 facilitate HIV-1 infection of murine cells. Pathobiology 59:361-371, 1991
10. Dragic T, Charneau P, Clavel F, Alizon M: Complementation of murine cells for human immunodeficiency virus envelope/CD4-mediated fusion in human/murine heterokaryons. J Virol 66: 4794-4802, 1992
11. Broder CC, Dimitrov DS, Blumenthal R, Berger EA: The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component(s). Virology 193:483-491, 1993
12. Harrington RD, Geballe AP: Cofactor requirement for human immunodeficiency virus type 1 entry into a CD4-expressing human cell line. J Virol 67:5939-5947, 1993
13. Ramarli D, Cambiaggi C, De Giuli Morghen C, Tripputi P, Ortolani R, Bolzanelli M, Tridente G, Accolla RS: Susceptibility of human-mouse T cell hybrids to HIV-productive infection. AIDS Res Hum Retrovirus 9:1269-1275, 1993
14. Dragic T, Alizon M: Different requirements for membrane fusion mediated by the envelopes of human immunodeficiency virus types 1 and 2. J Virol 67:2355-2359, 1993
15. Dragic T, Picard L, Alizon M: Proteinase-resistant factors in human erythrocyte membranes mediate CD4-dependent fusion with cells expressing human immunodeficiency virus type 1 envelope glycoproteins. J Virol 69:1013-1018, 1995
16. Alkhatib G, Combardiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA: CC-CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-1958, 1996
17. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath P, Lijun W, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodrosky J: The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148, 1996
18. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR: Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666, 1996
19. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673, 1996
20. Doranz BJ, Rucker J, Yi YJ, Smith RJ, Samson M, Peiper SC, Parmentier M, Cullman RG, Doms RW: A dual tropic primary isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3 and CKR-2B as fusion cofactors. Cell 85:1149-1158, 1996
21. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane. G-protein coupled receptor. Science 272:872-877, 1996
22. Berson JF, Long D, Doranz BJ, Rucker J, Jirik FR, Doms RW: A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 70:6288-629, 1996
23. Liao F, Alkhatib G, Peden KW, Sharma G, Berger EA, Farber JM: STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J Exp Med 185:2015-2023, 1997
24. Deng HK, Unutmaz D, KewalRamani VN, Littman DR: Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 388:296-300, 1997
25. Alkhatib G, Liao F, Berger EA, Farber JM, Peden KW: A new SIV co-receptor, STRL33. Nature 388:238, 1997
26. Farzan M, Choe H, Martin K, Marcon L, Hofmann W, Karlsson G, Sun Y, Barrett P, Marchand N, Sullivan N, Gerard N, Gerard C, Sodroski J: Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J Exp Med 186:405-411, 1997
27. Pleskoff O, Treboute C, Brelot A, Heveker N, Seman M, Alizon M: Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science 276: 1874-1878, 1997
28. Rucker J, Edinger AL, Sharron M, Samson M, Lee B, Berson JF, Yi Y, Margulies B, Collman RG, Doranz BJ, Parmentier M, Doms RW: Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol 71:8999-9007, 1997
29. Loetscher DF, Amara DF, Oberlin DF, Brass DF, Legler DF: TYMSTR, a putative receptor selectively expressed in activated T cells, exhibits HIV-1 coreceptor function. Curr Biol 7:652-660, 1997
30. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382: 829-833, 1996
31. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, Moser B: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382:833-835, 1996
32. Zhang L, Huang Y, He T, Cao Y, Ho DD: HIV subtype and second receptor use. Nature 383:768, 1996
33. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185:621-628, 1997
34. Kozak SL, Platt EJ, Madani N, Ferro FJ, Peden K, Kabat D: CD4, CXCR-4, and CCR-5 dependencies for infection by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol 71:873-882, 1997
35. Jansson M, Popovic M, Karlsson A, Cocchi F, Rossi P, Albert J, Wigzell H: Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci USA 93:15382-15387, 1996
36. Simmons G, Wilkinson D, Reeves JD, Dittmar MT, Beddows S, Weber J, Carnegie G, Desselberger U, Gray PW, Weiss RA, Clapham PR: Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol 70:8355-8360, 1996
37. Scarlatti et al: Nature Medicine, 1997
38. Bron R, Klasse PJ, Wilkinson D, Clapham PR, Pelchen-Matthews A, Power C, Wells TN, Kim J, Peiper SC, Hoxie JA, Marsh M: Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein. J Virol 71:8405-8415, 1997
39. He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, Busciglio J, Yang X, Hofmann W, Newman W, Mackay CR, Sodroski J, Gabuzda D: CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 385:645-649, 1997
40. Horuk R, Hesselgesser J, Zhou Y, Faulds D, Halks-Miller M, Harvey S, Taub D, Samson M, Parmentier M, Rucker J, Doranz BJ, Doms RW: The CC chemokine 1-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. J Biol Chem 273:386-391, 1998
41. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P: The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nature Med 2:1244-1247, 1996
42. Oravecz T, Pall M, Norcross MA: Beta-chemokine inhibition of monocytotropic HIV-1 infection. Interference with a postbinding fusion step. J Immunol 157:1329-1332, 1996
43. Speck RF, Wehrly K, Platt EJ, Atchison RE, Charo IF, Kabat D, Chesebro B, Goldsmith MA: Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol 71:7136-7139, 1997
44. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, Sodroski J: CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384: 179-183, 1996
45. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Science 384:184-187, 1996
46. Lapham CK, Ouyang J, Chandrasekhar B, Nguyen NY, Dimitrov DS, Golding H: Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Nature 274:602-605, 1996
47. Sattentau QJ, Zolla-Pazner S, Poignard P: Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 206: 713-717, 1995
48. Chan DC, Fass D, Berger JM, Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273, 1997
49. Amara A, Gall SL, Schwartz O, Salamero J, Montes M, Loetscher P, Baggiolini M, Virelizier JL, Arenzana-Seisdedos F: HIV coreceptor downregulation as antiviral principle: SDF-1 alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 186:139-146, 1997
50. Alkhatib G, Locati M, Kennedy PE, Murphy PM, Berger EA: HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: Independence from G protein signaling and importance of coreceptor downmodulation. Virology 234:340-348, 1997
51. Rucker J, Samson M, Doranz BJ, Libert F, Berson JF, Yi Y, Smyth RJ, Collman RG, Broder CC, Vassart G, Doms RW, Parmentier M: Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell 87:437-446, 1996
52. Atchison RE, Gosling J, Monteclaro FS, Franci C, Digilio L, Charo IF, Goldsmith MA: Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines. Science 274:1924-1926, 1996
53. Potempa S, Picard L, Reeves JD, Wilkinson D, Weiss RA, Talbot SJ: CD4-independent infection by human immunodeficiency virus type 2 strain ROD/B: The role of the N-terminal domain of CXCR-4 in fusion and entry. J Virol 71:4419-4424, 1997
54. Lu Z, Berson JF, Chen Y, Turner JD, Zhang T, Sharron M, Jenks MH, Wang Z, Kim J, Rucker J, Hoxie JA, Peiper SC, Doms RW: Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc Natl Acad Sci USA 94:6426-6431, 1997
55. Farzan M, Choe H, Martin KA, Sun Y, Sidelko M, Mackay CR, Gerard NP, Sodroski J, Gerard C: HIV-1 entry and macrophage inflammatory protein-1 beta-mediated signaling are independent functions of the chemokine receptor CCR5. J Biol Chem 272: 6854-6857, 1997
56. Edinger AL, Amedee A, Miller K, Doranz BJ, Endres M, Sharron M, Samson M, Lu ZH, Clements JE, Murphey-Corb M, Peiper SC, Parmentier M, Broder CC, Doms RW: Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. Proc Natl Acad Sci USA 94:4005-4010, 1997
57. Gosling J, Monteclaro FS, Atchison RE, Arai H, Tsou CL, Goldsmith MA, Charo IF: Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. Proc Natl Acad Sci USA 94:5061-5066, 1997
58. Arenzana-Seisdedos F, Virelizier JL, Rousset D, Clark-Lewis I, Loetscher P, Moser B, Baggiolini M: HIV blocked by chemokine antagonist. Nature 383:400, 1996
59. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, Buser R, Wells TNC, Proudfoot AE: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276:276-279, 1996
60. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F, Virelizier JL, Baggiolini M, Sykes BD, Clark-Lewis I: Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 16:6996-7007, 1997
61. Endres MJ, Clapham PR, Marsh M, Ahuja M, Turner JD, McKnight A, Thomas JF, Stoebenau-Huggarty B, Choe S, Vance PJ, Wells TN, Power CA, Sutterwala SS, Doms RW, Landau NR, Hoxie JA: CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 87:745-756, 1996
62. Wu L, LaRosa G, Kassam N, Gordon CJ, Heath H, Ruffing N, Chen H, Humblias J, Samson M, Parmentier M, Moore JP, Mackay CR: Interaction of chemokine receptor CCR5 with its ligands: Multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 186:1373-1381, 1997
63. Davis CB, Dikic I, Unutmaz D, Hill CM, Arthos J, Siani MA, Thompson DA, Schlessinger J, Littman DR: Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5. J Exp Med 186:1793-1798, 1997
64. Weissman D, Rabin RL, Arthos J, Rubbert A, Dybul M, Swofford R, Venkatesan S, Farber JM, Fauci A: Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 389:981-985, 1997
65. Chackerian B, Long EM, Luciw PA, Overbaugh J: Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J Virol 71:3932-3939, 1997
66. Garzino-Demo A, Arya SK, Devico AL, Cocchi F, Lusso P, Gallo RC: C-C Chemokine Rantes and HIV-LTR-driven gene expression. AIDS Res Hum Retrovirus 13:1367-1371, 1997
67. Leith JG, Copeland KF, McKay PJ, Richards CD, Rosenthal KL: CD8-T-cell-mediated suppression of HIV-1 long terminal repeat-driven gene expression is not modulated by the CC chemokines RANTES, macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta. AIDS 11:575-580, 1997
68. Copeland KF, Leith JG, McKay PJ, Rosenthal KL: CD8+ T cell supernatants of HIV type 1-infected individuals have opposite effects on long terminal repeat-mediated transcription in T cells and monocytes. AIDS Res Hum Retrovirus 13:71-77, 1997
69. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O'Brien SJ: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856-1862, 1996
70. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725, 1996
71. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, Koup RA: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med 2:1240-1243, 1996
72. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377, 1996
73. Zimmerman PA, Bucklerwhite A, Alkhatib G, Spalding T, Kubofcik JA, Combardiere C, Weissman DA, Cohen O, Rubbert AA, Lam G, Vaccarezza MA, Kennedy PE, Kumaraswami VA, Giorgi JV, Detels R, Hunter J, Chopek M, Berger EA, Fauci AS, Nutman TB, Murphy PM: Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor-5-studies in populations with contrasting clinical phenotypes, defined racial backgrounds, and quantified risk. Mol Med 3:23-36, 1997
74. Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, Sheppard HW: The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nature Med 3:338-340, 1997
75. Biti R, Ffrench R, Young J, Bennetts B, Stewart G, Liang T: HIV infection. Nature Med 3:252-253, 1997
76. Smith O: HIV CCR5 resistance incomplete. Nature Med 3:372-373, 1997
77. O'Brien TR, Winkler C, Dean M, Nelson JA, Carrington M, Michael NL, White GC: HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet 349:1219, 1997
78. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C: HIV-1 infection in an individual homozygous tor CCR5 delta 32. Lancet 349:1219-1220, 1997
79. Eugen-Olsen J, Iversen AKN, Garred P, Koppelhus U, Pedersen C, Benfield TL, Sorensen AM, Katzenstein T, Dickmeiss E, Gerstoft J, Skinhoi P, Svejgaard A, Nielsen JO, Hofmann B: Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals, AIDS 11:305-310, 1997
80. Katzenstein TL, Eugen-Olsen J, Hofmann B, Benfield T, Pedersen C, Iversen AK, Sorensen AM, Garred P, Koppelhus U, Svejgaard A, Gerstoft J: HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. J Acquir Immune Defic Syndr Hum Retrovirol 16:10-14, 1997
81. Meyer L, Magierowska M, Hubert JB, Rouzioux C, Deveau C, Sanson E, Debre P, Delfraissy JE, Theodorou I: Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: Relationship with viral load. AIDS 11:F73-F78, 1997
82. de Roda Husman AM, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, Bakker M, Roos MT, Prins M, de Wolf F, Coutinho RA, Miedema F, Goudsmit J, Schuitemaker H: Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 127:882-890, 1997
83. Benkirane M, Jin DY, Chun RF, Koup RA, Jeang KT: Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem 272:30603-30606, 1997
84. Quillent C, Oberlin E, Braun J, Rousset D, Gonzalez-Canali G, Metais P, Montagnier L, Virelizier JL, Arenzana-Seisdedos F, Beretta A: HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 351:14-18, 1998
85. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O'Brien TR, Jacobson LP, Kaslow R, Buchbinder S, Villinghoff E, Vlahov D, Hoots K, Hilgartner MW, O'Brien SJ: Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenler AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 277:959-965, 1997
86. Smith MW, Carrington M, Winkler C, Lomb D, Dean M, Huttley G, O'Brien SJ: CCR2 chemokine receptor and AIDS progression. Nature Med 3:1052-1053, 1997
87. Rizzardi GP, Morawetz RA, Vicenzi E, Ghezzi S, Poli G, Lazzarin A, Pantaleo G, the Swiss HIV Cohort: CCR-2 polymorphism and HIV disease. Nature Med 4:252-253, 1998
88. Kostrikis LG, Huang Y, Moore JP, Wolinsky SM, Zhang L, Guo Y, Deutsch L, Phair J, Neumann AU, Ho DD: Chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nature Med 4:350-353, 1998
89. Michael NL, Louie LG, Rohrbaugh AL, Schultz KA, Dayhoff DE, Wang CE, Sheppard HW: The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nature Med 3:1160-1162, 1997
90. Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, VanDevanter NL, Padian N, Braun JF, Kotler DP, Wolinsky SM, Koup RA: Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nature Med 2:412-417, 1996
91. Ponath PD, Qin S, Post TW, Wang J, Wu L, Gerard NP, Newman W, Gerard C, Mackay CR: Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 183:2437-2448, 1996
92. Daugherty BL, Siciliano SJ, DeMartino JA, Malkowitz L, Sirotina A, Springer MS: Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J Exp Med 183:2349-2354, 1996
93. Zanussi S, D'Andrea M, Simonelli C, Tirelli U, De Paoli P: Serum levels of RANTES and MIP-1 alpha in HIV-positive long-term survivors and progressor patients. AIDS 10:1431-1432, 1996
94. Weiss L, Si-Mohamed A, Giral P, Castiel P, Ledur A, Blondin C, Kazatchkine MD, Haeffner-Cavaillon N: Plasma levels of monocyte chemoattractant protein-1 but not those of macrophage inhibitory protein-1 alpha and RANTES correlate with virus load in human immunodeficiency virus infection. J Infect Dis 176: 1621-1624, 1997
95. McKenzie SW, Dallalio G, North M, Frame P, Means RT: Serum chemokine levels in patients with non-progressing HIV infection. AIDS 10:F29-F33, 1996
96. Malnati MS, Tambussi G, Clerici E, Polo S, Algeri M, Nardese V, Furci L, Lazzarin A, Lusso P: Increased plasma levels of the C-C chemokine RANTES in patients with primary HIV-1 infection. J Biol Regul Homeostatic Agents 11:40-42, 1998
97. Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM: Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 176:587-592, 1992
98. Power CA, Clemetson JM, Clemetson KJ, Wells TN: Chemokine and chemokine receptor mRNA expression in human platelets. Cytokine 7:479-482, 1995
99. Klinger MH, Wilhelm D, Bubel S, Sticherling M, Schroder JM, Kuhnel W: Immunocytochemical localization of the chemokines RANTES and MIP-1 alpha within human platelets and their release during storage. Int Arch Allergy Immunol 107:541-546, 1995
100. Bubel S, Wilhelm D, Entelmann M, Kirchner H, Kluter H: Chemokines in stored platelet concentrates. Transfusion 36:445-449, 1996
101. Webb LM, Ehrengruber MU, Clark-Lewis I, Baggiolini M, Rot A: Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci USA 90:7158-7162, 1993
102. Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S: T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature 361:79-82, 1993
103. Witt DP, Lander AD: Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Biol 4:394-400, 1994
104. Gilat D, Hershkoviz R, Mekori YA, Vlodavsky I, Lider O: Regulation of adhesion of CD4+ T lymphocytes to intact or heparinase-treated subendothelial extracellular matrix by diffusible or anchored RANTES and MIP-1 beta. J Immunol 153: 4899-4906, 1994
105. Luster AD, Greenberg SM, Leder P: The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 182:219-231, 1995
106. Blazevic V, Heino M, Ranki A, Jussila T, Krohn KJ: RANTES, MIP and interleukin-16 in HIV infection. AIDS 10:1435-1436, 1996
107. Mackewicz CE, Barker E, Greco G, Reyes-Teran G, Levy JA: Do beta-chemokines have clinical relevance in HIV infection? J Clin Invest 100:921-930, 1997
108. Schwartz DH, Castillo RC, Arango-Jaramillo S, Sharma UK, Song HF, Sridharan G: Chemokine-independent in vitro resistance to human immunodeficiency virus (HIV-1) correlating with low viremia in long-term and recently infected HIV-1-positive persons. J Infect Dis 176:1168-1174, 1997
109. Clerici M, Balotta C, Trabattoni D, Papagno L, Ruzzante S, Rusconi S, Fusi ML, Colombo MC, Galli M: Chemokine production in HIV-seropositive long-term asymptomatic individuals. AIDS 10:1432-1433, 1996
110. Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, Bizzini B, Gringeri A, Santagostino E, Rappaport J, Feldman M, O'Brien SJ, Bumy A, Gallo RC: C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 95:3857-3861, 1998
111. Ullum H, Cozzi A, Victor J, Aladdin A, Phillips AN, Gerstoft J, Skinhej P, Pedersen BK: Production of beta-chemokines in human immunodeficiency virus (HIV) infection: Evidence that high levels of macrophage inflammatory protein-1 beta are associated with a decreased risk of HIV disease progression. J Infect Dis 133:331-336, 1998
112. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, Dean M, Honjo T, Tashiro K, Yabe D, Buchbinder S, Vittinghoff E, Goedert JJ, O'Brien TR, Jacobson LP, Detels R, Donfield S, Willoughby A, Gomperts E, Vlahov D, Phair J, O'Brien SJ: Genetic restriction of AIDS pathogenesis by an SDF-1 chemokinc gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort. Science 279:389-393, 1998
113. Saha K, Bentsman G, Chess L, Volsky DJ: Endogenous production of beta-chemokines by CD4+, but not CD8+, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro. J Virol 72:876-881, 1998
114. Scala E, D'Offizi G, Rosso R, Turriziani O, Ferrara R, Mazzone AM, Antonelli G, Aiuti F, Paganelli R: C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. J Immunol 158:4485-4492, 1997
115. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278: 1447-1450, 1997
116. Furci L, Scarlatti G, Burastero S, Tambussi G, Colognesi C, Quillent C, Longhi R, Loverro P, Borgonovo B, Gaffi D, Carrow E, Malnati M, Lusso P, Siccardi AG, Lazzarin A, Beretta A: Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med 186:455-460, 1997
117. Lehner T, Wang Y, Cranage M, Bergmeier LA, Mitchell E, Tao L, Hall G, Dennis M, Cook N, Brookes R, Klavinskis L, Jones I, Doyle C, Ward R: Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nature Med 2:767-775, 1996
118. + lymphocytes can control HIV infection in vitro by suppressing viral replication. Science 234:1563-1566, 1996
119. + T cells. J Immunol 144:2961-2966, 1990
120. Walker CM, Moody DJ, Stites DP, Levy JA: CD8+ T lymphocyte control of HIV replication in cultured CD4+ cells varies among infected individuals. Cell Immunol 119:470-475, 1989
121. Mackewicz CE, Ortega HW, Levy JA: CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 87:1462-1466, 1991
122. Blackbourn DJ, Mackewicz CE, Barker E, Hunt TK, Herndier B, Haase AT, Levy JA: Suppression of HIV replication by lymphoid tissue CD8+ cells correlates with the clinical state of HIV-infected individuals. Proc Natl Acad Sci USA 93:13125-13130, 1996
123. Paliard X, Lee AY, Walker CM: RANTES, MIP-1 alpha and MIP-1 beta are not involved in the inhibition of HIV-ISF33 replication mediated by CDX+ T-cell clones. AIDS 10:1317-1321, 1996
124. Kinter AL, Ostrowski M, Goletti D, Oliva A, Weissman D, Gantt K, Hardy E, Jackson R, Ehler L, Fauci AS: HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines. Proc Natl Acad Sci USA 93:14076-14081, 1996
125. Rubbert A, Weissman D, Combadiere C, Pettrone KA, Daucher JA, Murphy PM, Fauci AS: Multifactorial nature of noncytolytic CD8+ T cell-mediated suppression of HIV replication: beta-chemokine-dependent and -independent effects. AIDS Res Hum Retrovirus 13:63-64, 1997
126. Moriuchi H, Moriuchi M, Combadiere C, Murphy PM, Fauci AS: CD8+ T-cell-derived soluble factor(s), but not beta-chemokines RANTES, MIP-1 alpha, and MIP-1 beta, suppress HIV-1 replication in monocyte/macrophages. Proc Natl Acad Sci USA 93:15341-15345, 1996
127. Lacey SF, McDanal CB, Horuk R, Greenberg ML: The CXC chemokine stromal cell-derived factor 1 is not responsible for CD8+ T cell suppression of syncytia-inducing strains of HIV-1. Proc Natl Acad Sci USA 94:9842-9847, 1997
128. Pal R, Garzino-Demo A, Markham PD, Burns J, Brown M, Gallo RC, DeVico AL: Inhibition of HIV-1 infection by the β chemokine MDC. Science 278:695-698, 1997
129. Godiska R, Chantry D, Raport CJ, Sozzani S, Allavena P, Leviten D, Mantovani A, Gray PW: Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med 185:1595-1604, 1997
130. Chang MS, McNinch J, Elias C III, Manthey CL, Grosshans D, Meng T, Boone T, Andrew DP: Molecular cloning and functional characterization of a novel CC chemokine, stimulated T cell chemotactic protein (STCP-1) that specifically acts on activated T lymphocytes. J Biol Chem 272:25229-25237, 1997
131. Kledal TN, Rosenkilde MM, Coulin F, Simmons G, Johnsen AH, Alouani S, Power CA, Luttichau HR, Gerstoft J, Clapham PR, Clark-Lewis I, Wells TNC, Schwartz TW: Broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 277:1656-1659, 1997
132. Boshoff C, Endo Y, Collins PD, Takeuchi Y, Reeves JD, Schweickart VL, Siani MA, Sasaki T, Williams TJ, Gray PW, Moore PS, Chang Y, Weiss RA: Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 278:290-294, 1997
133. Baggiolini M: Human chemokines: an update. Annu Rev Immunol 15:675-705, 1997
134. Oravecz T, Pall M, Wang J, Roderiquez G, Ditto M, Norcross MA: Regulation of anti-HIV-1 activity of RANTES by heparan sulfate proteoglycans. J Immunol 159:4587-4592, 1997
135. Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, Unsworth E, Norcross MA: Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 186:1865-1872, 1997
136. Gong JH, Uguccioni M, Dewald B, Baggiolini M, Clark-Lewis I: RANTES and MCP-3 antagonists hind multiple chemokine receptors. J Biol Chem 271:10521-10527, 1996
137. Proudfoot AE, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, Wells TN: Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 271:2599-2603, 1996
138. Wells TN, Guye-Coulin F, Bacon KB: Peptides from the amino-terminus of RANTES cause chemotaxis of human T-lymphocytes. Biochem Biophys Res Commun 211:100-105, 1996
139. Hebert CA, Vitangcol RV, Baker JB: Scanning mutagenesis of interleukin-8 identities a cluster of residues required for receptor binding. J Biol Chem 266:18989-18994, 1991
140. Clark-Lewis I, Schumacher C, Baggiolini M, Moser B: Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities. J Biol Chem 266:23128-23134, 1991
141. Zhang YJ, Rutledge BJ, Rollins BJ: Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis. J Biol Chem 269:15918-15924, 1994
142. Lusti-Narasimhan M, Chollet A, Power CA, Allet B, Proudfoot AE, Wells TN: A molecular switch of chemokine receptor selectivity. Chemical modification of the interleukin-8 Leu25 → Cys mutant. J Biol Chem 271:3148-3153, 1996
143. Beall CJ, Mahajan S, Kolattukudy PE: Conversion of monocyte chemoattractant protein-1 into a neutrophil attractant by substitution of two amino acids. J Biol Chem 267:3455-3459, 1992
144. Wells TNC, Proudfoot AEI, Power CA, Lusti-Narasimhan M, Alouani S, Hoogewerf AJ, Peitsch MC: The molecular basis of the chemokine/chemokine receptor interaction-scope for design of chemokine antagonists. Methods 10:126-134, 1996
145. Brelot A, Heveker N, Pleskoff O, Sol N, Alizon M: Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity. J Virol 71:4744-4751, 1997
146. Piccard et al: J Virol, 1997
147. Picard L, Wilkinson DA, McKnight A, Gray PW, Hoxie JA, Clapham PR, Weiss RA: Role of the amino-terminal extracellular domain of CXCR-4 in human immunodeficiency virus type 1 entry. Virology 231:105-111, 1997
148. Bieniasz PD, Fridell RA, Aramori I, Ferguson SS, Caron MG, Cullen BR: HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. EMBO J 16:2599-2609, 1997
149. Alkhatib G, Ahuja SS, Light D, Mummidi S, Berger EA, Ahuja SK: CC chemokine receptor 5-mediated signaling and HIV-1 co-receptor activity share common structural determinants. Critical residues in the third extracellular loop support HIV-1 fusion. J Biol Chem 272:19771-19776, 1997
150. Dragic T, Trkola A, Lin SW, Nagashima KA, Kajumo F, Zhao L, Olson WC, Wu L, Mackay CR, Allaway GP, Sakmar TP, Moore JP, Maddon PJ: Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol 72:279-285, 1998
151. Schols D, Struyf S, Van Damme J, Esle JA, Henson G, De Clercq E: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 186:1383-1388, 1997
152. Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, Yoshida N, Waki M, Matsumoto A, Yoshie O, Kishimoto T, Yamamoto N, Nagasawa T: A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 186:1389-1393, 1997
153. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, Doms RW, O'Brien WA: A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 186:1395-1400, 1997
154. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, DeClercq E, Moore JP: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Med 4:72-77, 1998
155. Chen JD, Bai X, Yang AG, Cong Y, Chen SY: Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy. Nature Med 3:1110-1116, 1997
156. Yang AG, Bai X, Huang XF, Yao C, Chen S: Phenotypic knockout of HIV type 1 chemokine coreceplor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc Natl Acad Sci USA 94:11567-11572, 1997
157. Endres MJ, Jaffer S, Haggarty B, Turner JD, Doranz, BJ, O'Brien PJ, Kolson DL, Hoxie JA: Targeting of HIV-and SIV-infected cells by CD4-chemokine receptor pseudotypes. Science 278: 1462-1464, 1997
158. Dolei A, Biolchini A, Serra C, Curreli S, Gomes E, Dianzani F: Increased replication of T-cell-tropic HIV strains and CXC-chemokine receptor-4 induction in T cells treated with macrophage inflammatory protein (MIP)-1 alpha, MIP-1 beta and RANTES beta-chemokines. AIDS 12:183-190, 1998
159. Conant K, Garzino-Demo A, Nath A, McArthur J, Halliday W, Power C, Gallo RC, Major EO: Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci USA 95:3117-3121, 1998